Inhibition of soluble epoxide hydrolase attenuates high-fat-diet-induced hepatic steatosis by reduced systemic inflammatory status in mice

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Liu, Yan ^a   Dang, Huaixin ^a   Li, Dan ^a   Pang, Wei ^a   Hammock, Bruce D ^b   Zhu, Yi ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [3 (1 ADAMANTYL)UREIDO]CYCLOHEXYLOXY]BENZOIC ACID; CYTOKINE; EPOXIDE HYDROLASE; MESSENGER RNA; SOLUBLE EPOXIDE HYDROLASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME INHIBITION; FATTY LIVER; GENE OVEREXPRESSION; HEPATITIS; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; LIPID DIET; LIPID STORAGE; MACROPHAGE MIGRATION; MALE; MOUSE; NONHUMAN; UPREGULATION; WEIGHT GAIN;

ADIPOSE TISSUE; ANIMALS; DIETARY FATS; EPOXIDE HYDROLASES; FATTY LIVER; INFLAMMATION; MACROPHAGES; MICE; SOLUBILITY;

EID: 84862243951     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039165     Document Type: Article

References (41)

1. Busch L, Miozza V, Sterin-Borda L, Borda E, (2009) Increased leukotriene concentration in submandibular glands from rats with experimental periodontitis. Inflamm Res 58: 423-430.
2. Chitturi S, Farrell GC, (2007) Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health. J Gastroenterol Hepatol 22: 967-969.
3. Gentile CL, Pagliassotti MJ, (2008) The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 19: 567-576.
4. Fishbein MH, Mogren C, Gleason T, Stevens WR, (2006) Relationship of hepatic steatosis to adipose tissue distribution in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 42: 83-88.
5. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, et al. (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115: 1343-1351.
6. Pantanetti P, Garrapa GG, Mantero F, Boscaro M, Faloia E, et al. (2004) Adipose tissue as an endocrine organ? A review of recent data related to cardiovascular complications of endocrine dysfunctions. Clin Exp Hypertens 26: 387-398.
7. Fain JN, Bahouth SW, Madan AK, (2004) TNFalpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord 28: 616-622.
8. Freedland ES, (2004) Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr Metab 1: 12.
9. Imig JD, Hammock BD, (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8: 794-805.
10. Daikh BE, Lasker JM, Raucy JL, Koop DR, (1994) Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp Ther 271: 1427-1433.
11. Scarborough PE, Ma J, Qu W, Zeldin DC, (1999) P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev 31: 205-234.
12. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, et al. (2009) Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol 297: F740-748.
13. Node K, Huo Y, Ruan X, Yang B, Spiecker M, et al. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276-1279.
14. Deng Y, Theken KN, Lee CR, (2010) Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol 48: 331-341.
15. Morisseau C, Inceoglu B, Schmelzer K, Tsai HJ, Jinks SL, et al. (2010) Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J Lipid Res 51: 3481-3490.
16. Jump DB, Botolin D, Wang Y, Xu J, Demeure O, et al. (2008) Docosahexaenoic acid (DHA) and hepatic gene transcription. Chem Phys Lipids 153: 3-13.
17. Morin C, Sirois M, Echave V, Rizcallah E, Rousseau E, (2009) Relaxing effects of 17(18)-EpETE on arterial and airway smooth muscles in human lung. Am J Physiol Lung Cell Mol Physiol 296: L130-139.
18. Sato K, Emi M, Ezura Y, Fujita Y, Takada D, et al. (2004) Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. J Hum Genet 49: 29-34.
19. De Taeye BM, Morisseau C, Coyle J, Covington JW, Luria A, et al. (2009) Expression and Regulation of Soluble Epoxide Hydrolase in Adipose Tissue. Obesity 18: 489-498.
20. Liu J-Y, Tsai H-J, Hwang SH, Jones PD, Morisseau C, et al. (2009) Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Brit J Pharmacol 156: 284-296.
21. Iyer A, Kauter K, Alam MA, Hwang SH, Morisseau C, et al. (2012) Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats. Exp Diabetes Res 2012: 758614.
22. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, et al. (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275: 40504-40510.
23. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82: 4196-4200.
24. Zhang LN, Vincelette J, Cheng Y, Mehra U, Chen D, et al. (2009) Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler Thromb Vasc Biol 29: 1265-1270.
25. Luria A, Bettaieb A, Xi Y, Shieh GJ, Liu HC, et al. (2011) Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A 108: 9038-9043.
26. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD, (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39: 690-694.
27. Ai D, Pang W, Li N, Xu M, Jones PD, et al. (2009) Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A 106: 564-569.
28. Luo P, Chang HH, Zhou Y, Zhang S, Hwang SH, et al. (2010) Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther 334: 430-438.
29. Ai D, Fu Y, Guo D, Tanaka H, Wang N, (2007) Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A 104: 9018-9023.
30. Iyer A, Fairlie DP, Prins JB, Hammock BD, Brown L, (2010) Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol 6: 71-82.
31. Endo M, Masaki T, Seike M, Yoshimatsu H, (2007) TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp Biol Med (Maywood) 232: 614-621.
32. Lee YS, Li P, Huh JY, Hwang IJ, Lu M, et al. (2011) Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes 60: 2474-2483.
33. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808.
34. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830.
35. Maachi M, Pieroni L, Bruckert E, Jardel C, Fellahi S, et al. (2004) Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 28: 993-997.
36. Liu JY, Li N, Yang J, Qiu H, Ai D, et al. (2010) Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc Natl Acad Sci U S A 107: 17017-17022.
37. Fer M, Dreano Y, Lucas D, Corcos L, Salaun JP, et al. (2008) Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450. Arch Biochem Biophys 471: 116-125.
38. Morin C, Sirois M, Echave V, Albadine R, Rousseau E, (2010) 17,18-epoxyeicosatetraenoic acid targets PPARgamma and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung: role of soluble epoxide hydrolase. Am J Respir Cell Mol Biol 43: 564-575.
39. Xu X, Zhao CX, Wang L, Tu L, Fang X, et al. (2010) Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice. Diabetes 59: 997-1005.
40. Luria A, Weldon SM, Kabcenell AK, Ingraham RH, Matera D, et al. (2007) Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem 282: 2891-2898.
41. Wolf NM, Morisseau C, Jones PD, Hock B, Hammock BD, (2006) Development of a high-throughput screen for soluble epoxide hydrolase inhibition. Anal Biochem 355: 71-80.